Evox Therapeutics Limited
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Evox Therapeutics Limited - overview
Established
2016
Location
Oxford, -, UK
Primary Industry
Biotechnology
About
Evox Therapeutics Limited, based in the UK, focuses on developing innovative therapeutics for severe neurological diseases utilizing its proprietary ExoEdit™ technology, aimed at addressing significant unmet medical needs in this critical healthcare sector. Founded in 2016 in Oxford, UK, Evox Therapeutics Limited specializes in exosome-based therapeutics for treating neurological disorders. The firm has engaged in 5 deals, with the most recent funding round being a Series C in February 2021, where it raised GBP 69. 2 mn led by Redmile Group.
The company is led by CEO Antonin de Fougerolles, who continues to guide its strategic direction. Evox Therapeutics specializes in innovative therapeutics aimed at treating severe neurological and neurodegenerative diseases through its proprietary ExoEdit™ technology. The core product offerings involve an advanced CRISPR/Cas-based gene editing system encapsulated within exosome-based nanoparticles, allowing for targeted gene knockdown of mutations associated with various neurological disorders. This addresses critical areas of unmet medical need, focusing on providing transformative treatment options for patients suffering from life-threatening conditions, primarily targeting markets in North America and Europe.
In the most recent year, 2023, Evox Therapeutics reported a revenue of GBP 11,464,568. 90 and an EBITDA of GBP -20,934,752. 90. The company operates on a partnership model, generating revenue through strategic collaborations with biopharmaceutical companies and research institutions, facilitating the advancement of its product pipeline.
Evox Therapeutics is dedicated to advancing its exosome-based therapeutics pipeline, particularly through the continuation of its DeliverEX platform aimed at rare diseases. The recent Series C funding, raised in February 2021, will support these initiatives, ensuring the progression of multiple therapeutic candidates. The company is also looking to expand into new markets, specifically targeting North America and Europe for broader outreach in delivering treatments for neurological disorders.
Current Investors
Healthcare Royalty Partners, Borealis Ventures, GV
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Molecular Science, Genetics & Gene Therapy, Pharmaceutical Research & Development
Website
www.evoxtherapeutics.com
Company Stage
Series C
Total Amount Raised
Subscriber access only
Evox Therapeutics Limited - timeline of key events
Evox Therapeutics Limited - financials
| Fiscal Year Ended | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | - | - | - | - | 6,585,690 | 22,258,384 | 7,171,222 | - | - | - |
| % Revenue Growth (YoY) | - | - | - | - | - | 238.0% | (67.8%) | - | - | - |
| EBITDA (USD) | - | - | (5,951,371) | (8,749,835) | (9,854,782) | (5,916,919) | (23,585,158) | - | - | - |
| Operating Income (USD) | - | - | (6,149,952) | (9,188,932) | (10,894,312) | (7,728,977) | (25,727,211) | - | - | - |
| Operating Margin | - | - | - | - | (165.4%) | (34.7%) | (358.8%) | - | - | - |
| % EBITDA Margin | - | - | - | - | (149.6%) | (26.6%) | (328.9%) | - | - | - |
| NET Income (USD) | (1,003,849) | (2,660,577) | (4,954,293) | (7,229,549) | (8,512,746) | (2,720,827) | (18,555,059) | - | - | - |
| % Net Margin | - | - | - | - | (129.3%) | (12.2%) | (258.7%) | - | - | - |
Evox Therapeutics Limited - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.